These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34710389)

  • 1. Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris.
    Tovanabutra N; Bax CE; Feng R; Kushner CJ; Payne AS
    J Invest Dermatol; 2022 Apr; 142(4):1058-1064.e7. PubMed ID: 34710389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
    Brown AE; Motaparthi K; Hsu S
    Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
    De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
    Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
    Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
    Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study.
    Miše J; Jukić IL; Marinović B
    Front Immunol; 2022; 13():884931. PubMed ID: 35592312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
    España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
    Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus.
    Bozca BC; Bilgiç A; Uzun S
    J Dermatolog Treat; 2022 Jun; 33(4):2102-2109. PubMed ID: 34027788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris.
    Sinistro A; Calabresi V; Lupi F; Sera F; Frezzolini A; Ruffelli M; De Pità O; Camaioni D; Cianchini G; Di Zenzo G
    Eur J Dermatol; 2015; 25(6):578-85. PubMed ID: 26552329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rituximab induced remission of pemphigus vulgaris: 2 cases].
    Borel C; Launay F; Garrouste C; Astudillo L; Bazex J; Arlet P; Paul C; Viraben R; Sailler L
    Rev Med Interne; 2007 Apr; 28(4):266-8. PubMed ID: 17188405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab.
    Ahmed AR; Shetty S
    Autoimmun Rev; 2015 Apr; 14(4):323-31. PubMed ID: 25499920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of rituximab therapy in pemphigus.
    Shimanovich I; Baumann T; Schmidt E; Zillikens D; Hammers CM
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2884-2889. PubMed ID: 32367562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.
    Róbert L; Kovács A; Sárdy M; Fábián M
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):156-157. PubMed ID: 38439728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Juvenile pemphigus vulgaris].
    Janisson-Dargaud D; Reguiaï Z; Perceau G; Eschard C; Bernard P
    Ann Dermatol Venereol; 2008 Dec; 135(12):843-7. PubMed ID: 19084695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemphigus.
    Schmidt E; Kasperkiewicz M; Joly P
    Lancet; 2019 Sep; 394(10201):882-894. PubMed ID: 31498102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.
    Kushner CJ; Wang S; Tovanabutra N; Tsai DE; Werth VP; Payne AS
    JAMA Dermatol; 2019 Dec; 155(12):1404-1409. PubMed ID: 31642878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
    Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study.
    Russo I; Miotto S; Saponeri A; Alaibac M
    Expert Opin Biol Ther; 2020 Jun; 20(6):673-678. PubMed ID: 32027810
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.
    Baum S; Gilboa S; Greenberger S; Pavlotsky F; Trau H; Barzilai A
    J Dermatolog Treat; 2013 Dec; 24(6):427-30. PubMed ID: 23521340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in pemphigus.
    Hebert V; Joly P
    Immunotherapy; 2018 Jan; 10(1):27-37. PubMed ID: 29064314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.